Savara Inc , a clinical stage biopharmaceutical company, focuses on rare respiratory diseases.
infoSavara is a small cap stock with a total market cap of 515.01M.
infoThey trade on the NASDAQ and had their IPO 6 years and 3 months ago.
infoSavara currently employs 28 people.
infoAs of Wednesday, Aug 23 2023, Savara’s share price is $3.81.
News Relating to Savara
Seeking Alpha
Savara: A Speculative Play
Sunday Jul 16 2023 at 11:50
Today, we circle back on a small development firm called Savara for the first time in over two years. Its primary drug candidate is being developed for a rare affliction that has no approved therapies and has a pivotal readout coming up in the second quarter of 2024. An update investment analysis around Savara follows in the paragraphs below.
Business Wire
Savara to Present at the Jefferies Healthcare Conference
Friday Jun 02 2023 at 08:05
AUSTIN, Texas–(BUSINESS WIRE)–Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Jefferies Healthcare Conference on June 9, 2023 at 10:30 am ET/7:30 am PT. A live webcast of the fireside chat will be available on Savara’s website at http://www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days. About Savara Savara is a clinical s.
The Motley Fool
Why Shares of Savara Jumped on Tuesday
Tuesday May 16 2023 at 12:32
Savara is a clinical-stage pharmaceutical company with no revenue. The company expects a top-line readout on molgramostim in the second quarter of 2024.
Business Wire
Savara to Present at the Oppenheimer 33rd Annual Healthcare Conference
Monday Mar 06 2023 at 16:05
AUSTIN, Texas–(BUSINESS WIRE)–Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023 at 1:20pm ET. A live webcast of the presentation will be available on Savara’s website at http://www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days.
The Motley Fool
Why Shares of Savara Soared This Week
Friday Jan 27 2023 at 15:47
The clinical-stage biopharmaceutical company focuses on therapies to treat rare respiratory diseases.
Business Wire
Savara to Present at H.C. Wainwright 24th Annual Global Investment Conference
Thursday Sep 01 2022 at 08:05
AUSTIN, Texas–(BUSINESS WIRE)–Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Matt Pauls, Chair and CEO, Savara will present at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022. A webcast of the presentation will be available at 7:00 AM ET/4:00 AM PT on September 12, 2022 on Savara’s website at http://www.savarapharma.com/investors/events-presentations/ and archived for 90 d
Zacks Investment Research
3 Top Breakout Stocks to Add to Your Portfolio Now
Friday Jul 08 2022 at 08:33
Savara (SVRA), LGL Group (LGL) and Harte Hanks (HHS) have been selected as the breakout stocks for today.
Business Wire
Savara to Present at Jefferies Healthcare Conference
Wednesday Jun 01 2022 at 16:05
AUSTIN, Texas–(BUSINESS WIRE)–Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Jefferies Healthcare Conference on June 8, 2022 at 1:00 pm ET in New York City. A live webcast of the presentation will be available on Savara’s website at http://www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceuti
Zacks Investment Research
After Golden Cross, Savara Inc. (SVRA)’s Technical Outlook is Bright
Monday May 23 2022 at 11:18
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Business Wire
Savara to Present at Oppenheimer’s 32nd Annual Healthcare Conference
Wednesday Mar 09 2022 at 08:05
AUSTIN, Texas–(BUSINESS WIRE)–Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at Oppenheimer’s 32nd Annual Healthcare Conference on March 16, 2022 at 3:20 pm ET. A live webcast of the presentation will be available on Savara’s website at http://www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical
Business Wire
Savara to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
Tuesday Jan 04 2022 at 08:05
AUSTIN, Texas–(BUSINESS WIRE)–Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright BIOCONNECT Virtual Conference being held January 10-13, 2022. A webcast of the presentation will be available at 7:00 AM ET/4:00 AM PT on January 10, 2022 on Savara’s website at http://www.savarapharma.com/investors/events-presentations/ and archived for 90 days. About Savara Savara is a
Business Wire
Savara to Present at the Jefferies London Healthcare Conference
Wednesday Nov 10 2021 at 08:05
AUSTIN, Texas–(BUSINESS WIRE)–Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Jefferies London Healthcare Conference being held November 16-19, 2021. A pre-recorded, on-demand webcast of Savara’s presentation will be available on the conference website beginning Thursday, November 18 at 3:00 am ET through Friday, November 19 at 12:00 pm ET. Additionally, a replay of the pr
Business Wire
Savara to Present at the Inaugural Piper Sandler Lung Day
Thursday Oct 07 2021 at 16:05
AUSTIN, Texas–(BUSINESS WIRE)–Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a Fireside Chat at the Inaugural Piper Sandler Lung Day on Friday, October 15, 2021 at 10:30 am ET / 7:30 am PT. Following the event, a replay of the webcast will be available through the Investors page of Savara’s website at http://www.savarapharma.com/investors/events-presentations/ and will be archiv
Business Wire
Savara to Participate in Two Upcoming Investor Healthcare Conferences
Tuesday Sep 07 2021 at 08:05
AUSTIN, Texas–(BUSINESS WIRE)–Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the following healthcare conferences: H.C. Wainwright 23rd Annual Global Investment Conference: A pre-recorded webcast of the presentation will be available beginning at 7:00 AM ET / 4:00 AM PT on September 13, 2021. Oppenheimer Fall Healthcare Life Sciences & MedTech Summit: A live webcast of th
Business Wire
Savara Announces New Employment Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Friday Sep 03 2021 at 08:05
AUSTIN, Texas–(BUSINESS WIRE)–Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees. On September 2, 2021, the Compensation Committee of Savara’s Board of Directors granted inducement awards to two new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 200,000 shares of the Company’s common stock and restricted
Business Wire
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Friday Aug 20 2021 at 08:05
AUSTIN, Texas–(BUSINESS WIRE)–Savara Inc. (NASDAQ: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees. On August 16, 2021, the Compensation Committee of Savara’s Board of Directors granted inducement awards to two new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 200,000 shares of the Company’s common stock and restricted st
Benzinga
5 Penny Stocks Insiders Are Buying
Thursday Aug 19 2021 at 08:01
When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Business Wire
Savara Reports Second Quarter 2021 Financial Results and Provides Business Update
Thursday Aug 12 2021 at 16:05
AUSTIN, Texas–(BUSINESS WIRE)–Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today reported financial results for the second quarter ending June 30, 2021 and provided a business update. “Over the last 9 months we streamlined our portfolio, reduced and restructured the organization, and significantly strengthened the balance sheet so that we could focus solely on advancing the pivotal Phase 3 IMPALA 2 clinical trial,” said Matt Paul
Zacks Investment Research
Savara (SVRA) Initiates Dosing in Pivotal Lung Disorder Study
Thursday Jul 01 2021 at 11:17
Savara (SVRA) is developing its lead pipeline candidate, molgramostim, as a potential treatment for autoimmune pulmonary alveolar proteinosis.
Business Wire
Savara Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial
Wednesday Jun 30 2021 at 10:47
AUSTIN, Texas–(BUSINESS WIRE)–Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the first patient has been dosed in the pivotal IMPALA-2 clinical trial. IMPALA-2 is a Phase 3 trial designed to evaluate the efficacy and safety of molgramostim compared to placebo. Molgramostim is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). The trial is expected to be conduct
Seeking Alpha
Savara: They Failed Once, But They Are Trying Again
Monday Jun 07 2021 at 15:03
Savara failed a key phase 3 trial in aPAP.
Business Wire
Savara to Present at the Jefferies Virtual Healthcare Conference
Wednesday May 26 2021 at 08:05
AUSTIN, Texas–(BUSINESS WIRE)–Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Savara management will be presenting at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 10:00 AM ET / 7:00 AM PT. Interested parties can access a live audio webcast on the Investors page of the Savara website at http://www.savarapharma.com/investors/events-presentations/. Please connect to the Company’s website at le
24/7 Wall Street
Oppenheimer Has 5 Sizzling Biotech Stocks to Buy Now Trading Under $10
Saturday May 22 2021 at 06:15
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
Business Wire
Savara to Present at the Oppenheimer Rare & Orphan Disease Virtual Summit
Monday May 17 2021 at 08:05
AUSTIN, Texas–(BUSINESS WIRE)–Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Savara management will be presenting at the Oppenheimer Rare & Orphan Disease Virtual Summit on Friday, May 21, 2021 at 12:25 PM ET / 9:25 AM PT. Interested parties can access a live audio webcast on the Investors page of the Savara website at http://www.savarapharma.com/investors/events-presentations/. Please connect to the Company’s web
Business Wire
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Friday May 14 2021 at 08:05
AUSTIN, Texas–(BUSINESS WIRE)–Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that on May 11, 2021, the Compensation Committee of the Company’s Board of Directors granted a newly hired employee the option to purchase 175,000 shares of the Company’s common stock and restricted stock units (RSUs) covering 100,000 shares of the Company’s common stock. These equity awards were granted pursuant to Rule 5635(c)(4) of the N
InvestorPlace
7 Reddit Penny Stocks to Buy for a Biotech Boom
Friday Apr 16 2021 at 13:52
So, which biotech penny stocks, popular with the Reddit set, offer such opportunity? Consider these seven as ones with potential to live up to online enthusiasm.
InvestorPlace
7 Penny Stocks with Interesting Catalysts
Friday Apr 09 2021 at 11:12
While penny stocks are always incredibly risky ventures, these publicly traded companies offer interesting catalysts to consider. The post 7 Penny Stocks with Interesting Catalysts appeared first on InvestorPlace.
InvestorPlace
7 Reddit Penny Stocks to Keep Your Eye on for Big Movement
Wednesday Mar 24 2021 at 13:07
Reddit stocks — and in particular Reddit penny stocks — are some of the riskiest shares out there. Yet, investors could make out big with some of the names on this list.
InvestorPlace
7 Reddit Penny Stocks Seeing the Most Chatter Today
Thursday Mar 18 2021 at 12:40
Retail investors over on Reddit Penny Stocks are showing interest in quite a few interesting players today that investors will want to note. The post 7 Reddit Penny Stocks Seeing the Most Chatter Today appeared first on InvestorPlace.
Pulse2
SVRA Stock Price Increases Over 10% Pre-Market: Why It Happened
Wednesday Mar 17 2021 at 06:58
The stock price of Savara Inc (NASDAQ: SVRA) is trading at above 10% pre-market. This is why it happened.
Savara Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Savara’s Altman Z-score is 5.17 which is in the safe zone. This indicates the company is financially stable and less likely to experience financial distress or bankruptcy.
Derived from SEC.GOV filing dataopen_in_new
Savara Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, 10 insiders have bought $10.00M of common stock in Savara on the stock market with no insider selling.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Savara’s Income Quality of 0.68 is in line with its Industry Group of 0.69 (-1.4% lower)
Savara’s Income Quality of 0.68 is in line with its Major Industry Group of 0.71 (-4.2% lower)
Savara’s Income Quality of 0.68 is in line with its Sector of 0.75 (-9.3% lower)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Savara’s Current Ratio of 18.33 is greater than its Industry Group of 4.76 (285.1% greater)
Savara’s Current Ratio of 18.33 is greater than its Major Industry Group of 4.32 (324.3% greater)
Savara’s Current Ratio of 18.33 is greater than its Sector of 2.6 (605.0% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-12.56 & -1.27)
Cannot compare a negative PE Ratio (-12.56 & -1.1)
Cannot compare a negative PE Ratio (-12.56 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Savara’s PB Ratio of 5.87 is greater than its Industry Group of 1.34 (338.1% greater)
Savara’s PB Ratio of 5.87 is greater than its Major Industry Group of 1.4 (319.3% greater)
Savara’s PB Ratio of 5.87 is greater than its Sector of 1.62 (262.3% greater)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Savara’s ROE of -0.47 is in line with its Industry Group of -0.44 (-6.8% lower)
Savara’s ROE of -0.47 is lower than its Major Industry Group of -0.38 (-23.7% lower)
Savara’s ROE of -0.47 is lower than its Sector of -0.03 (-1466.7% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Savara’s ROCE of -0.4 is in line with its Industry Group of -0.42 (4.8% greater)
Savara’s ROCE of -0.4 is in line with its Major Industry Group of -0.37 (-8.1% lower)
Savara’s ROCE of -0.4 is lower than its Sector of -0.04 (-900.0% lower)
Derived from SEC.GOV filing dataopen_in_new